J. Mackintosh (Brisbane (QLD), Australia), M. Kokosi (London, United Kingdom), Y. Uzunhan (Bobigny, France), D. Visca (Tradate, Italy)
LSC - 2018 - In vivo models of Drug Induced ILD; tools to study and improve drug safety
I. Mahmutovic Persson, H. Falk HåKansson (hanna@trulylabs.com / Truly Labs AB, M. Village,Lund), P. öNnervik (per-ola@trulylabs.com / Truly Labs AB, M. Village,Lund), J. Persson (janne@trulylabs.com / Truly Labs AB, M. Village,Lund), L. E. Olsson (lars.e_olsson@med.lu.se / Department of Translational Medicine, M. Radiation Physics, L. University, M. Sweden,Malmö), K. Von Wachenfeldt (karin@trulylabs.com / Truly Labs AB, M. Village,Lund)
|  |
Association between 4-metre gait speed and isometric knee extension muscle strength in patients with interstitial lung disease
K. Nemoto (Ibaraki, Japan), S. Oh-Ishi (Ibaraki, Japan), Y. Yabuuchi (Ibaraki, Japan), M. Nonaka (Ibaraki, Japan), H. Goto (Ibaraki, Japan), N. Arai (Ibaraki, Japan), Y. Sasatani (Ibaraki, Japan), H. Tachi (Ibaraki, Japan), T. Akiyama (Ibaraki, Japan), H. Ishikawa (Ibaraki, Japan), K. Hyodo (Ibaraki, Japan), Y. Miura (Ibaraki, Japan), I. Hase (Ibaraki, Japan), K. Hayashihara (Ibaraki, Japan), T. Saito (Ibaraki, Japan), S. Fukai (Ibaraki, Japan)
| |
Factors predicting response to azathioprine in chronic hypersensitivity pneumonitis – the importance of BAL lymphocytosis
S. Raimundo (Vila Real, Portugal), N. Melo (Porto, Portugal), P. Mota (Porto, Portugal), S. GuimarãEs (Porto, Portugal), C. Souto Moura (Porto, Portugal), R. Cunha (Porto, Portugal), J. Pereira (Porto, Portugal), A. Morais (Porto, Portugal)
|  |
Parasympathetic Nervous System withdrawal in patients with Interstitial Lung Disease but not in COPD patients
K. Rigatto (Porto Alegre, Brazil), A. Machado Duarte (Porto Alegre, Brazil), C. Mostarda (Maranhão, Brazil), P. Zimermann Teixeira (Porto Alegre, Brazil)
| |
Acute exacerbation of ILD: an Indian tertiary centre experience
J. Mullerpattan (Mumbai, India), P. Sheth (Mumbai, India), A. Joshi (Mumbai, India), Z. Udwadia (Mumbai, India)
| |
What does bronchoalveolar lavage add to cryobiopsy in interstitial lung disease?
C. Serra (Barcelona, Spain), P. Millan Billi (Barcelona, Spain), V. Pajares Ruiz (Barcelona, Spain), T. Franquet Casas (Barcelona, Spain), L. López Vilaró (Barcelona, Spain), C. Burrel Deicke (Barcelona, Spain), A. Alonso León (Barcelona, Spain), A. Torrego Fernandez (Barcelona, Spain), D. Castillo Villegas (Barcelona, Spain)
| |
Usefulness of pulsed cyclophosphamide in Interstitial Lung Disease (ILD)
C. Kong (Portsmouth, United Kingdom), O. Adeagbo (Portsmouth, United Kingdom), R. Hooper (Portsmouth, United Kingdom), V. Titmuss (Portsmouth, United Kingdom), S. Babu (Portsmouth, United Kingdom)
| |
Interstitial lung diseases misdiagnosis: a Healthcare Improvement Science (HIS) approach
R. Crisan-Dabija (Iasi, Romania), T. Mihaescu (Iasi, Romania)
| |
CORRELATION BETWEEN LUNG AND JOINT INVOLVEMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND INTERSTITIAL LUNG DISEASE: CROSS SECTIONAL STUDY
F. Paulin (Buenos Aires, Argentina), M. Alberti (Buenos Aires, Argentina), F. Caro (Buenos Aires, Argentina), M. Fernandez (Buenos Aires, Argentina), J. Mercado (PA, United States of America), L. Fassola (Buenos Aires, Argentina)
| |
Positive correlation between sympathetic modulation and peace in patients with interstitial lung disease
K. Rigatto (Porto Alegre, Brazil), A. Machado Duarte (Porto Alegre, Brazil), C. Mostarda (Maranão, Brazil), G. Watte (Porto Alegre, Brazil), G. Lucchetti (Porto Alegre, Brazil), P. Zimmermann Teixeira (Porto Alegre, Brazil)
| |
Connective tissue disease-related interstitial lung disease and lung cancer
M. Alvarenga Santos (Lisboa, Portugal), S. Clemente (Lisboa, Portugal), M. Felizardo (Lisboa, Portugal), S. Furtado (Lisboa, Portugal)
| |
Joint Rheumatology and Chest Clinic in a District General Hospital
N. Kewalramani (Manchester, United Kingdom), A. Umar (Manchester, United Kingdom), G. Chelliah (Manchester, United Kingdom), A. Ashish (Manchester, United Kingdom), L. Bell (Manchester, United Kingdom)
| |
An audio-imaging approach to measure the degree of severity of patients suffering from DPLD disease
A. Mondal (Mangalore, India), P. Banerjee (Mangalore, India)
| |
A case of diffuse alveolar hemorrhage after illegal vaginal injection of hyaluronic acid
S. Lee (Seoul, Republic of Korea), M. Kang (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), S. Han (Seoul, Republic of Korea), J. Hwang (Seoul, Republic of Korea), Y. Jo (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), M. Park (Seoul, Republic of Korea)
| |
Surgical biopsy results of our patients with diffuse parenchymal lung diseases
G. Okumus (Istanbul, Turkey), B. Ozkan (Istanbul, Turkey), Z. Bingol (Istanbul, Turkey), M. Ulker (Istanbul, Turkey), B. Karatekin (Istanbul, Turkey), E. Kiyan (Istanbul, Turkey), Z. Kilicaslan (Istanbul, Turkey), M. Kara (Istanbul, Turkey), D. YiLmazbayhan (Istanbul, Turkey), A. Toker (Istanbul, Turkey)
| |
Autoimmunity in Interstitial lung diseases: preliminary data from a tertiary center.
E. Vivarelli (Florence, Italy), G. Vitiello (Florence, Italy), F. Tinghi (Florence, Italy), D. Malandrino (Florence, Italy), B. Palterer (Florence, Italy), E. Torricelli (Florence, Italy), E. Bargagli (Florence, Italy), E. Rosi (Florence, Italy), P. Parronchi (Florence, Italy)
| |
Revisiting the diagnostic approach of Hypersensitivity Pneumonitis
A. Fernandes (Matosinhos, Portugal), J. Ferreira (Matosinhos, Portugal), I. Neves (Matosinhos, Portugal)
| |
Pirfenidone as a treatment for asbestos-related lung fibrosis? A retrospective case series
F. Rytz (Bern, Switzerland), A. Poellinger (Bern, Switzerland), S. Berezowska (Bern, Switzerland), T. Geiser (Bern, Switzerland), M. Funke-Chambour (Bern, Switzerland)
| |
Interventions to improve symptom control and quality of life in patients with interstitial lung disease: a systematic review and meta-analysis
S. Bajwah (London, United Kingdom), J. Colquitt (Southampton, United Kingdom), E. Loveman (Southampton, United Kingdom), C. Bausewein (Munich, Germany), H. Almond (London, United Kingdom), A. Oluyase (London, United Kingdom), A. Wells (London, United Kingdom)
| |
Clinical features of dermatitis, myositis and severe ILD. Could the AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom?
P. KAVOURA (ATHENS, Greece), A. Frimas (ATHENS, Greece), P. Kithreotis (ATHENS, Greece), C. Bagos (ATHENS, Greece), S. Kanellas (ATHENS, Greece), D. Veldekis (ATHENS, Greece)
| |